Global Immuno-oncology Therapy Market, 2016-2022: Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines and Others

DUBLIN, May 16, 2018 /PRNewswire/ --

The "Immuno-oncology Therapy Market by Therapy Type and by Therapeutic Areas, for Hospitals, Clinics and Cancer Research Institutes: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.

The study provides a decisive view on the immuno-oncology therapy market by segmenting the market based on therapy type, therapeutic area, end-user, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2016 to 2022.

Scope of the Report

• Based on therapy type the market is segmented into monoclonal antibodies, immune checkpoint inhibitors (PD1/ PDL1 and CTLA-4), immune system modulators, cancer vaccines and others.
• Based on the therapeutic area the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, blood cancer and other cancers.
• Key end-users covered under this study include hospitals, clinics, ASCs and cancer research institutes.
• This segmentation includes demand for immuno-oncology therapy market based on individual therapy type, therapeutic area and end-users in all the regions and countries.

Market Dynamics

Market Drivers

• Highly Promising Treatment Pipeline
• Increase in Number of Patients Suffering from Various Cancers
• Greater Efficiency Over Conventional Treatment Methods

Market Restraints

• High Level of Attrition within the Development Cycles
• Stringent Regulatory Framework
• Lack of Awareness of Immunotherapy

Opportunities

• Developed Economies Showing Higher Development Rates

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Immuno-oncology Therapy Market Market Dynamics

4. Global Immuno-oncology Therapy Market Competitive Landscape

5. Global Immuno-oncology Therapy Market Therapy Type Segment Analysis

6. Global Immuno-oncology Therapy Market Therapeutic Area Segment Analysis

7. Global Immuno-oncology Therapy Market End-User Segment Analysis

8. Global Immuno-oncology Therapy Market Regional Segment Analysis

9. Company Profiles

• Amgen, Inc.
• AstraZeneca Plc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F.Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc.
• Janssen Biotech
• Merck and Co.
• Novartis AG
• Pfizer, Inc.
• Sanofi
• Spectrum Pharmaceuticals, Inc.
• Takeda Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/32d4kf/global?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-immuno-oncology-therapy-market-2016-2022-monoclonal-antibodies-immune-checkpoint-inhibitors-immune-system-modulators-cancer-vaccines-and-others-300649731.html

SOURCE Research and Markets